Company Overview
IN8bio, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to the discovery, development, and commercialization of gamma-delta T cell product candidates designed for the treatment of cancer and autoimmune diseases. The company functions within the broader Healthcare sector, specifically the Biotechnology industry, where it pursues innovative therapeutic solutions rather than established revenue streams from marketed products. Its current scale is defined by a market capitalization of $13.88M, an employee count of 17, and reported annual revenue that is not available for the trailing twelve months. The valuation metrics indicate that the company remains in an early-stage development phase, as the lack of reported revenue suggests that financial returns are currently derived primarily from capital markets rather than product sales or licensing deals.
Financial Health
The company reported a net income of $-19,440,000 and an EBITDA of $-18,090,000 over the trailing twelve months, while specific revenue figures are not available for the period in question. The substantial gap between the reported net income and EBITDA reveals a significant tax benefit or other non-operating gains that offset the operational losses, yet the underlying business model continues to generate negative earnings typical of pre-commercial biotechnology firms. Free cash flow stands at $-5,547,125, indicating that the company is consuming cash to fund its research and development activities rather than generating liquidity from operations. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, which reflects the standard accounting treatment for clinical-stage entities that have not yet achieved commercial sales or have recorded revenue that does not cover direct costs in a way that generates a positive percentage. The balance sheet shows $27.09M in cash against $2.78M in debt, resulting in a debt-to-equity ratio of 10.10, which suggests a highly leveraged classification relative to traditional industries, though the absolute debt load is manageable given the cash position. A current ratio of 8.82 demonstrates robust short-term liquidity, indicating that the company possesses ample current assets to cover its short-term obligations without immediate refinancing needs. Return on Equity is -92.5% and Return on Assets is -46.6%, metrics that mathematically reflect the loss-making nature of the business and indicate that management effectiveness in generating profit is currently negated by the high costs associated with clinical trials and product development.
Valuation Assessment
Valuation multiples for IN8bio, Inc. include a P/E Ratio (TTM) that is not available due to negative earnings, while the forward P/E is listed as -0.94, implying that expected earnings in the near future are projected to remain negative based on the current valuation model. The price-to-book ratio is 0.50, which indicates that the market values the company at half of its book value, suggesting a significant discount relative to the asset base or reflecting high uncertainty regarding the future commercial potential of its product pipeline. Alternative valuation metrics such as the price-to-sales ratio, which is not available, and an EV/EBITDA of 0.58 are used to assess the company, with the low EV/EBITDA figure often seen in distressed or high-growth pre-revenue situations where earnings are deeply negative. The stock has traded between a 52-week high of $7.20 and a 52-week low of $1.17, placing the current market price within a wide range that highlights significant volatility common in biotech equities. The beta value is recorded as 0.00, which technically implies no correlation to market movements in the data provided, though this is often an artifact of low liquidity or limited data points for small-cap biotechnology stocks rather than a true reflection of zero volatility.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as not available, which prevents a direct comparison of whether earnings are growing faster or slower than revenue; however, the absence of these growth rates confirms the company is in a phase where historical financial performance data is insufficient for trend analysis. The company does not pay a dividend, evidenced by a dividend yield of not available and a payout ratio of 0.0%, meaning there are no cash distributions to shareholders. Because the company does not distribute income, the entire focus of its financial strategy is on reinvesting its cash reserves and equity capital into advancing its gamma-delta T cell product candidates toward commercialization. The overall growth and income profile is characterized by a complete reliance on external capital to fund operations, with no current mechanism for generating shareholder yield through dividends or organic earnings expansion.